Authors
Latest:
Prostate Cancer Test Is Missing Early Disease in Transgender WomenA UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.
Latest:
Dr Son on Urinary and Bowel Anastomotic Leak in Bladder CancerYoung Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.
Latest:
A Challenge to Medical Oncology Training Programs: Promote Equity in TrainingIn her 2020 American Society of Clinical Oncology presidential address, “Equity: Every patient. Every day. Everywhere,” Lori J. Pierce, MD, challenges medical oncology to imagine a future when equity is considered a humanistic standard of oncology practice.
Latest:
Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple MyelomaMichael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.
Latest:
Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AMLSanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.
Latest:
Dr Ahn on Outcomes With Ovarian Function Suppression in HER2+ Breast CancerSung Gwe Ahn, MD, PhD, discusses an exploratory analysis of ovarian function suppression in patients with HR-positive, HER2-positive breast cancer.
Latest:
Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCCAndrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.
Latest:
Dr. Sharifi on Methodologies Utilized to Evaluate Link Between Gut Microbiome and Fatal Prostate CancerNima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.
Latest:
Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FLPeter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.
Latest:
Monitoring and Follow-Up of Patients with Chronic GVHDThe panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
Latest:
Dr. Patel on the Association Between Ki-67 and Race in Early Breast CancerRima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.
Latest:
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCCAdam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.
Latest:
Dr Melstrom on Challenges Implementing Widespread Molecular Testing in GI CancerLaleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.
Latest:
Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast CancerMridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.
Latest:
FDA Approvals of Immunotherapy in Gynecology OncologyIn this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Latest:
Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ MelanomaThach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.
Latest:
Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LADr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.
Latest:
Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple MyelomaFenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr Karam on Key Kidney Cancer Takeaways From the 2023 IKCSJose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.
Latest:
Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FLSteven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.
Latest:
Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ TransplantMichael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.
Latest:
Discussion of RESORCE TrialPanelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
Latest:
Unmet Needs in SM TreatmentThe panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
Latest:
Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCPDrs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Latest:
Dr. Ligon on Delivering CAR T-cell Therapy via Mediport Lines in Pediatric B-Cell MalignanciesJohn Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.
Latest:
Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced MelanomaInderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AMLBradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
.jpg?fit=crop&auto=format)
